Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $4,820 MXN
Change Today 0.00 / 0.00%
Volume 0.0
BIIB* On Other Exchanges
As of 4:09 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by BIOGEN INC (BIIB*) in the last 6 months

Announced 07/16/15
75.00M for Eisai Inc., Research Triangle Park (RTP) Manufacturing Campus

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Research Triangle Park (RTP) manufacturing campus from Eisai Inc. on July 15, 2015. Under the terms of the agreement, Biogen will continue to manufacture oral solid-dose products for Eisai. In addition, Eisai has entered into a new manufacturing agreement whereby Biogen will manufacture Eisai's parenteral products. The property ownership transfer comprises all buildings on the campus. The parenteral ...
Read More

BIIB*'s price was unchanged after the transaction was announced on 07/16/15.
Investor / Buyer
Biogen Inc.
Creditor / Lender
Eisai Inc.
Announced 07/2/15
30.00M for Applied Genetic Technologies Corporation
Private Placement

Applied Genetic Technologies Corporation (NasdaqGM:AGTC) announced that it has entered into an agreement for a private placement of 1,453,981 common shares with new investor Biogen Inc. at $20.63 per share for gross proceeds of $30,000,000 on July 2, 2015. The transaction is expected to close in the third quarter of 2015.

BIIB*'s price was unchanged after the transaction was announced on 07/2/15.
Investor / Buyer
Biogen Inc.
Announced 05/7/15
5.00B for Biogen Inc.

Biogen Inc. (NasdaqGS:BIIB) announces a share repurchase program. Under the program, the company will repurchase up to $5,000 million worth of its common stock. The repurchased shares will be retired. The share repurchase program does not have an expiration date. The company currently expects that purchases will be executed within a period of up to five years. The Board of Directors of Biogen Inc. has authorized a buyback plan on May 7, 2015. On May 7, 2015, the ...
Read More

BIIB*'s price was unchanged after the transaction was announced on 05/7/15.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIIB*:MM $4,819.89 MXN 0.00

BIIB* Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $40.65 USD -0.74
Astellas Pharma Inc ¥1,585 JPY +8.00
Celgene Corp $111.24 USD -5.38
Shire PLC 4,524 GBp -80.00
Thermo Fisher Scientific Inc $123.64 USD -2.91
View Industry Companies

Industry Analysis


Industry Average

Valuation BIIB* Industry Range
Price/Earnings 19.6x
Price/Sales 6.6x
Price/Book 5.4x
Price/Cash Flow 17.5x
TEV/Sales 6.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at